Hologic Inc. announced strong fiscal second quarter results for 2022, posting adjusted earnings per share (EPS) of $2.07, exceeding the Zacks Consensus Estimate of $1.55 by 33.6%. While adjusted EPS declined 20.1% year-over-year and overall revenues fell 6.6%, the company's GYN Surgical and Molecular Diagnostics segments showed growth driven by over 3,000 Panther instruments. Hologic also raised its full-year revenue guidance to between $4.60 billion and $4.70 billion and maintains a robust cash position of $2.29 billion.
“Hologic’s global Molecular Diagnostics revenues · are expected to reflect · the benefits of Panther instruments · more than 3,000”
“Hologic’s GYN Surgical business arm · is expected to have registered · strong growth · in the fiscal second quarter”
“Zacks Consensus Estimate for Hologic’s second-quarter earnings per share · is pegged at · earnings per share · $1.55”
“Hologic, Inc. · reported · second-quarter fiscal 2022 adjusted earnings per share (EPS) · $2.07, down 20.1% year over year”
“Hologic, Inc. · surpassed · the Zacks Consensus Estimate · by 33.6%”
“Hologic, Inc. · had · GAAP EPS · $1.80”
“Hologic, Inc. · projected revenues for third-quarter fiscal 2022 · within · $875-$915 million”
“Hologic, Inc. · estimated adjusted EPS for the quarter · within · 67-72 cents”
“Hologic, Inc. · ended the second quarter of fiscal 2022 with cash and cash equivalents · $2.29 billion”
“Hologic has raised · the financial guidance for full-year 2022”
“Hologic’s global Molecular Diagnostics revenues · expected to reflect · benefits of Panthers · more than 3,000 Panther instruments installed globally”
“Hologic’s GYN Surgical business · expected to have registered · strong growth · true”